Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T03963
(Former ID: TTDI01291)
|
|||||
| Target Name |
Heat shock protein 90 (HSP90)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 7 Target-related Diseases | + | ||||
| 1 | Asthma [ICD-11: CA23] | |||||
| 2 | Multiple sclerosis [ICD-11: 8A40] | |||||
| 3 | Acute myeloid leukaemia [ICD-11: 2A60] | |||||
| 4 | COVID-19 [ICD-11: 1D6Y] | |||||
| 5 | Malignant haematopoietic neoplasm [ICD-11: 2B33] | |||||
| 6 | Motor neuron disease [ICD-11: 8B60] | |||||
| 7 | Neuropathy [ICD-11: 8C0Z] | |||||
| BioChemical Class |
Heat shock protein
|
|||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 4 Clinical Trial Drugs | + | ||||
| 1 | RNS-60 | Drug Info | Phase 2 | Asthma | [2] | |
| 2 | ADX-1612 | Drug Info | Phase 1 | Coronavirus Disease 2019 (COVID-19) | [3] | |
| 3 | LAM-003 | Drug Info | Phase 1 | Acute myeloid leukaemia | [4] | |
| 4 | RTA 901 | Drug Info | Phase 1 | Diabetic neuropathy | [5] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | RNS-60 | Drug Info | [1] | |||
| Inhibitor | [+] 3 Inhibitor drugs | + | ||||
| 1 | ADX-1612 | Drug Info | [6] | |||
| 2 | LAM-003 | Drug Info | [7] | |||
| 3 | RTA 901 | Drug Info | [8] | |||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Revalesio. | |||||
| REF 2 | ClinicalTrials.gov (NCT01714089) Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis. U.S. National Institutes of Health. | |||||
| REF 3 | Clinical pipeline report, company report or official report of Aldeyra Therapeutics | |||||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 5 | ClinicalTrials.gov (NCT02666963) A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults. U.S. National Institutes of Health. | |||||
| REF 6 | Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice. Int J Mol Sci. 2023 Mar 6;24(5):5014. | |||||
| REF 7 | LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 Nov 26;3(22):3661-3673. | |||||
| REF 8 | Clinical pipeline report, company report or official report of Reata Pharmaceuticals. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.